Swedish Orphan Biovitrum Valuation

Q: What is the Fair Price of SOBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SOBI (SEK326.2) is trading below our estimate of [[fair value]] (SEK1182.06)

Is SOBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOBI (SEK326.2) is trading below our estimate of fair value (SEK1182.06)

Significantly Below Fair Value: SOBI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOBI?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SOBI. This is calculated by dividing SOBI's market cap by their current preferred multiple.
What is SOBI's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 112.27b

SOBI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.4x
Enterprise Value/EBITDA	16x
PEG Ratio	2x

Price to Earnings Ratio vs Peers

How does SOBI's PE Ratio compare to its peers?

The above table shows the PE ratio for SOBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	74.8x
BIOG B BioGaia	28.2x	7.6%	SEK 11.3b
BONEX Bonesupport Holding	68.3x	31.2%	SEK 19.7b
CAMX Camurus	168.6x	75.0%	SEK 37.6b
NBIX Neurocrine Biosciences	34.3x	29.3%	US$11.6b
SOBI Swedish Orphan Biovitrum	52.3x	25.9%	SEK 112.3b

Price-To-Earnings vs Peers: SOBI is good value based on its Price-To-Earnings Ratio (52.3x) compared to the peer average (74.8x).

Price to Earnings Ratio vs Industry

How does SOBI's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	46.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	46.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: SOBI is expensive based on its Price-To-Earnings Ratio (52.3x) compared to the European Biotechs industry average (26x).

Price to Earnings Ratio vs Fair Ratio

What is SOBI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOBI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	52.3x
Fair PE Ratio	71.9x

Price-To-Earnings vs Fair Ratio: SOBI is good value based on its Price-To-Earnings Ratio (52.3x) compared to the estimated Fair Price-To-Earnings Ratio (71.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOBI forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 326.20	SEK 325.55 -0.2%	8.9%	SEK 370.00	SEK 250.00	n/a	11
Sep ’25	SEK 320.00	SEK 328.00 +2.5%	8.5%	SEK 370.00	SEK 250.00	n/a	11
Aug ’25	SEK 278.00	SEK 328.30 +18.1%	8.9%	SEK 370.00	SEK 250.00	n/a	10
Jul ’25	SEK 285.80	SEK 329.60 +15.3%	6.2%	SEK 370.00	SEK 285.00	n/a	10
Jun ’25	SEK 282.40	SEK 320.00 +13.3%	9.4%	SEK 370.00	SEK 252.00	n/a	10
May ’25	SEK 285.40	SEK 317.22 +11.2%	9.8%	SEK 370.00	SEK 252.00	n/a	9
Apr ’25	SEK 267.20	SEK 317.70 +18.9%	9.6%	SEK 370.00	SEK 252.00	n/a	10
Mar ’25	SEK 260.80	SEK 317.91 +21.9%	9.2%	SEK 370.00	SEK 252.00	n/a	11
Feb ’25	SEK 278.00	SEK 316.20 +13.7%	8.0%	SEK 345.00	SEK 252.00	n/a	10
Jan ’25	SEK 267.00	SEK 297.00 +11.2%	6.0%	SEK 325.00	SEK 252.00	n/a	10
Dec ’24	SEK 250.60	SEK 293.00 +16.9%	7.0%	SEK 325.00	SEK 252.00	n/a	10
Nov ’24	SEK 234.00	SEK 287.45 +22.8%	10.0%	SEK 325.00	SEK 222.00	n/a	11
Oct ’24	SEK 223.40	SEK 285.55 +27.8%	10.0%	SEK 325.00	SEK 222.00	n/a	11
Sep ’24	SEK 211.00	SEK 284.18 +34.7%	10.1%	SEK 325.00	SEK 222.00	SEK 320.00	11
Aug ’24	SEK 205.80	SEK 288.27 +40.1%	9.8%	SEK 325.00	SEK 222.00	SEK 278.00	11
Jul ’24	SEK 210.40	SEK 286.80 +36.3%	10.4%	SEK 325.00	SEK 216.00	SEK 285.80	10
Jun ’24	SEK 212.00	SEK 285.80 +34.8%	10.6%	SEK 325.00	SEK 216.00	SEK 282.40	10
May ’24	SEK 249.40	SEK 287.20 +15.2%	11.5%	SEK 325.00	SEK 211.00	SEK 285.40	10
Apr ’24	SEK 241.50	SEK 269.78 +11.7%	9.6%	SEK 305.00	SEK 211.00	SEK 267.20	9
Mar ’24	SEK 240.40	SEK 269.78 +12.2%	9.6%	SEK 305.00	SEK 211.00	SEK 260.80	9
Feb ’24	SEK 230.70	SEK 253.56 +9.9%	12.5%	SEK 305.00	SEK 203.00	SEK 278.00	9
Jan ’24	SEK 215.70	SEK 249.10 +15.5%	11.9%	SEK 295.00	SEK 200.00	SEK 267.00	10
Dec ’23	SEK 226.70	SEK 250.60 +10.5%	12.2%	SEK 295.00	SEK 200.00	SEK 250.60	10
Nov ’23	SEK 206.20	SEK 250.60 +21.5%	12.2%	SEK 295.00	SEK 200.00	SEK 234.00	10
Oct ’23	SEK 215.60	SEK 255.00 +18.3%	10.1%	SEK 295.00	SEK 203.00	SEK 223.40	10
Sep ’23	SEK 233.00	SEK 253.33 +8.7%	9.0%	SEK 280.00	SEK 203.00	SEK 211.00	9

Analyst Forecast: Target price is lower than the current share price.